Pliant Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Pliant Therapeutics, Inc. filed a Current Report on Form 8-K dated January 12, 2021, reporting a board appointment under Item 5.02. The company is a Delaware corporation headquartered in South San Francisco, California, with common stock traded on Nasdaq under the symbol PLRX.
Material event and compensation
- The board appointed David Pyott as an independent director effective January 12, 2021.
- Mr. Pyott will serve in the director class whose term expires at the 2021 annual meeting of stockholders.
- Upon appointment, he received an option to purchase 26,573 shares of common stock at an exercise price of $27.71 per share, equal to the closing market price on the appointment date.
- The option vests in 36 equal monthly installments over three years, subject to continued service.
- The company entered into an indemnification agreement with Mr. Pyott in substantially the same form used for its other directors.
Financial metrics, liquidity, and debt
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, balance-sheet data, or financial guidance. It also does not report a change in financial results versus a prior comparable period.
Management commentary, risks, and unusual items
Mr. Pyott brings more than 30 years of global pharmaceutical leadership experience, including service as chairperson and chief executive officer of Allergan, Inc. He also serves on the boards of Alnylam Pharmaceuticals and BioMarin Pharmaceutical and in other corporate and nonprofit leadership roles.
The filing states that there are no arrangements or understandings with other persons regarding his appointment, no family relationships with the company’s directors or executive officers, and no related-party transaction requiring disclosure under Item 404(a) of Regulation S-K.
Investor verification items
- Verify the number of shares subject to the option, the $27.71 exercise price, and the monthly vesting schedule.
- Assess the potential dilution from the 26,573-share equity award and any subsequent director compensation disclosures.
- Confirm Mr. Pyott’s independence status and service on other public-company boards.
- Review subsequent filings for changes to the board, option terms, or related indemnification arrangements.